Chlorophyll derivatives from marine cyanobacteria with lipid-reducing activities

Detalhes bibliográficos
Autor(a) principal: Freitas, S.
Data de Publicação: 2019
Outros Autores: Silva, N.G., Sousa, M.L., Ribeiro, T., Rosa, F., Leão, P.N., Vasconcelos, V., Reis, M.A., Urbatzka, R.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/130451
Resumo: Marine organisms, particularly cyanobacteria, are important resources for the production of bioactive secondary metabolites for the treatment of human diseases. In this study, a bioassay-guided approach was used to discover metabolites with lipid-reducing activity. Two chlorophyll derivatives were successfully isolated, the previously described 132-hydroxy-pheophytin a (1) and the new compound 132-hydroxy-pheofarnesin a (2). The structure elucidation of the new compound 2 was established based on one- and two-dimensional (1D and 2D) NMR spectroscopy and mass spectrometry. Compounds 1 and 2 showed significant neutral lipid-reducing activity in the zebrafish Nile red fat metabolism assay after 48 h of exposure with a half maximal effective concentration (EC50) of 8.9 ± 0.4 µM for 1 and 15.5 ± 1.3 µM for 2. Both compounds additionally reduced neutral lipid accumulation in 3T3-L1 multicellular spheroids of murine preadipocytes. Molecular profiling of mRNA expression of some target genes was evaluated for the higher potent compound 1, which indicated altered peroxisome proliferator activated receptor gamma (PPARγ) mRNA expression. Lipolysis was not affected. Different food materials (Spirulina, Chlorella, spinach, and cabbage) were evaluated for the presence of 1, and the cyanobacterium Spirulina, with GRAS (generally regarded as safe) status for human consumption, contained high amounts of 1. In summary, known and novel chlorophyll derivatives were discovered from marine cyanobacteria with relevant lipid-reducing activities, which in the future may be developed into nutraceuticals.
id RCAP_43613ed3c2292e3cbf46501807b743d1
oai_identifier_str oai:repositorio-aberto.up.pt:10216/130451
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Chlorophyll derivatives from marine cyanobacteria with lipid-reducing activitiesAnti-obesity drugsChlorophyll derivativesMurine pre-adipocytesPPARγZebrafish Nile red fat metabolism assayMarine organisms, particularly cyanobacteria, are important resources for the production of bioactive secondary metabolites for the treatment of human diseases. In this study, a bioassay-guided approach was used to discover metabolites with lipid-reducing activity. Two chlorophyll derivatives were successfully isolated, the previously described 132-hydroxy-pheophytin a (1) and the new compound 132-hydroxy-pheofarnesin a (2). The structure elucidation of the new compound 2 was established based on one- and two-dimensional (1D and 2D) NMR spectroscopy and mass spectrometry. Compounds 1 and 2 showed significant neutral lipid-reducing activity in the zebrafish Nile red fat metabolism assay after 48 h of exposure with a half maximal effective concentration (EC50) of 8.9 ± 0.4 µM for 1 and 15.5 ± 1.3 µM for 2. Both compounds additionally reduced neutral lipid accumulation in 3T3-L1 multicellular spheroids of murine preadipocytes. Molecular profiling of mRNA expression of some target genes was evaluated for the higher potent compound 1, which indicated altered peroxisome proliferator activated receptor gamma (PPARγ) mRNA expression. Lipolysis was not affected. Different food materials (Spirulina, Chlorella, spinach, and cabbage) were evaluated for the presence of 1, and the cyanobacterium Spirulina, with GRAS (generally regarded as safe) status for human consumption, contained high amounts of 1. In summary, known and novel chlorophyll derivatives were discovered from marine cyanobacteria with relevant lipid-reducing activities, which in the future may be developed into nutraceuticals.MDPI20192019-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/130451engISSN 1660-3397https://doi.org/10.3390/md17040229Freitas, S.Silva, N.G.Sousa, M.L.Ribeiro, T.Rosa, F.Leão, P.N.Vasconcelos, V.Reis, M.A.Urbatzka, R.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T14:36:08Zoai:repositorio-aberto.up.pt:10216/130451Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:04:54.957307Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Chlorophyll derivatives from marine cyanobacteria with lipid-reducing activities
title Chlorophyll derivatives from marine cyanobacteria with lipid-reducing activities
spellingShingle Chlorophyll derivatives from marine cyanobacteria with lipid-reducing activities
Freitas, S.
Anti-obesity drugs
Chlorophyll derivatives
Murine pre-adipocytes
PPARγ
Zebrafish Nile red fat metabolism assay
title_short Chlorophyll derivatives from marine cyanobacteria with lipid-reducing activities
title_full Chlorophyll derivatives from marine cyanobacteria with lipid-reducing activities
title_fullStr Chlorophyll derivatives from marine cyanobacteria with lipid-reducing activities
title_full_unstemmed Chlorophyll derivatives from marine cyanobacteria with lipid-reducing activities
title_sort Chlorophyll derivatives from marine cyanobacteria with lipid-reducing activities
author Freitas, S.
author_facet Freitas, S.
Silva, N.G.
Sousa, M.L.
Ribeiro, T.
Rosa, F.
Leão, P.N.
Vasconcelos, V.
Reis, M.A.
Urbatzka, R.
author_role author
author2 Silva, N.G.
Sousa, M.L.
Ribeiro, T.
Rosa, F.
Leão, P.N.
Vasconcelos, V.
Reis, M.A.
Urbatzka, R.
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Freitas, S.
Silva, N.G.
Sousa, M.L.
Ribeiro, T.
Rosa, F.
Leão, P.N.
Vasconcelos, V.
Reis, M.A.
Urbatzka, R.
dc.subject.por.fl_str_mv Anti-obesity drugs
Chlorophyll derivatives
Murine pre-adipocytes
PPARγ
Zebrafish Nile red fat metabolism assay
topic Anti-obesity drugs
Chlorophyll derivatives
Murine pre-adipocytes
PPARγ
Zebrafish Nile red fat metabolism assay
description Marine organisms, particularly cyanobacteria, are important resources for the production of bioactive secondary metabolites for the treatment of human diseases. In this study, a bioassay-guided approach was used to discover metabolites with lipid-reducing activity. Two chlorophyll derivatives were successfully isolated, the previously described 132-hydroxy-pheophytin a (1) and the new compound 132-hydroxy-pheofarnesin a (2). The structure elucidation of the new compound 2 was established based on one- and two-dimensional (1D and 2D) NMR spectroscopy and mass spectrometry. Compounds 1 and 2 showed significant neutral lipid-reducing activity in the zebrafish Nile red fat metabolism assay after 48 h of exposure with a half maximal effective concentration (EC50) of 8.9 ± 0.4 µM for 1 and 15.5 ± 1.3 µM for 2. Both compounds additionally reduced neutral lipid accumulation in 3T3-L1 multicellular spheroids of murine preadipocytes. Molecular profiling of mRNA expression of some target genes was evaluated for the higher potent compound 1, which indicated altered peroxisome proliferator activated receptor gamma (PPARγ) mRNA expression. Lipolysis was not affected. Different food materials (Spirulina, Chlorella, spinach, and cabbage) were evaluated for the presence of 1, and the cyanobacterium Spirulina, with GRAS (generally regarded as safe) status for human consumption, contained high amounts of 1. In summary, known and novel chlorophyll derivatives were discovered from marine cyanobacteria with relevant lipid-reducing activities, which in the future may be developed into nutraceuticals.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/130451
url https://hdl.handle.net/10216/130451
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv ISSN 1660-3397
https://doi.org/10.3390/md17040229
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799135973334843393